The combination of chemotherapy with PD‐L1 downregulation has been shown to amplify the therapeutic benefits of ICD.[24] Our group recently demonstrated the combination chemo‐immunotherapy of DOX and 5‐carboxy‐8‐hydroxyquinoline (IOX1, a histone demethylase inhibitor) through DOX‐triggered ICD and IOX1‐induced PD‐L1 downregulation in cancer cells, liberating the suppression of T cells and generating long‐term antitumor efficacy.[24a] Nonetheless, cof chemotherapeutics and PD‐L1 downregulators is hurdled by their different and uncontrolled drug release profiles. The gene discussed is CD274; the disease is cancer.